Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Sponsor

Virginia Commonwealth University (Other)

Overall Status

Recruiting

CT.gov ID

NCT03919292

Collaborator

Puma Biotechnology, Inc. (Industry)

113

Enrollment

Location

Arms

Anticipated Duration (Months)

1.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To determine the recommended phase 2 dose (RP2D) of the combination of neratinib and sodium valproate when given to patients with advanced solid tumors. Then to explore the antitumor effects of the neratinib and sodium valproate combination in advanced solid tumors with attention to RAS-mutated tumors, EGFR-altered GBM, and ocular melanoma, as part of the phase 2 expansion cohort.

Condition or Disease	Intervention/Treatment	Phase
Solid Tumor, Adult	Drug: Neratinib Drug: Divalproex Sodium	Phase 1/Phase 2

Detailed Description

The purpose of this trial is to test the safety of combining 2 drugs, neratinib (Nerlynx) and divalproex sodium (Depakote DR), also commonly called valproate, when treating patients with advanced cancer.

In an earlier stage of this trial the purpose was to test different doses of neratinib in combination with divalproex sodium to see which doses should be used in future research trials. This trial will also help us to learn how advanced tumors respond to the combination of neratinib and divalproex sodium.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

113 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers

Actual Study Start Date :

May 1, 2019

Anticipated Primary Completion Date :

Dec 31, 2023

Anticipated Study Completion Date :

Dec 31, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Neratinib + Divalproex Sodium - Dose Escalation Cohort Neratinib by mouth (PO) once daily + Divalproex Sodium (Valproate) by mouth (PO) twice daily on days 1-28 of each course.	Drug: Neratinib Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study. Other Names: Nerlynx Drug: Divalproex Sodium Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Other Names: Depakote Valproate
Experimental: Colon Colon Cancer (RAS-mutated) - Phase II dose expansion at recommended phase II dose (RP2D)	Drug: Neratinib Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study. Other Names: Nerlynx Drug: Divalproex Sodium Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Other Names: Depakote Valproate
Experimental: Glioblastoma (GBM) Glioblastoma with a RAS-mutation or EGFR alteration at RP2D	Drug: Neratinib Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study. Other Names: Nerlynx Drug: Divalproex Sodium Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Other Names: Depakote Valproate
Experimental: Ocular Melanoma (OM) Phase II dose expansion at RP2D	Drug: Neratinib Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study. Other Names: Nerlynx Drug: Divalproex Sodium Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Other Names: Depakote Valproate
Experimental: Other Cancer "Other Cancer" (RAS-mutated) at RP2D	Drug: Neratinib Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study. Other Names: Nerlynx Drug: Divalproex Sodium Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Other Names: Depakote Valproate
Experimental: Pancreatic Cancer RAS-mutated pancreatic cancer at RP2D	Drug: Neratinib Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study. Other Names: Nerlynx Drug: Divalproex Sodium Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Other Names: Depakote Valproate

Outcome Measures

Primary Outcome Measures

Determination of Recommended Phase 2 Dose (RP2D) [28 Days]
RP2D for the combination of neratinib and sodium valproate that is less than or the same as the maximum tolerated dose (MTD).

Secondary Outcome Measures

Evaluation of Treatment Related Adverse Events of Neratinib combined with Sodium Valproate [13 Months]
Determine the safety and toxicity of the combination of neratinib and sodium valproate by the number of participants with serious adverse events, and types of events as assessed by utilizing the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.
Solid Tumor Antitumor Effects [13 Months]
Phase 2 advanced solid tumor cohorts only: Evaluate number of participants with tumor response based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1), in patients evaluable for response.
Glioblastoma Antitumor Effects [13 Months]
Phase 2 GBM cohort only: Evaluate number of participants with tumor control based on objective response based on Response Assessment in Neuro-Oncology (RANO) criteria or Macdonald criteria, or disease control defined as PFS ≥ 6-month in patients evaluable for response
Progression Free Survival (PFS) [13 Months]
Evaluate the number of participants with progression free survival (PFS) defined as the duration of time from start of combination treatment (Cycle 1, Day 1) to date of progression.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Phase 1 - Dose Escalation Phase: Advanced solid tumor that has progressed during or after treatment with approved therapies or for which there is no standard effective therapy available
Phase 2 - Dose Expansion Phase: One of the following advanced solid tumors that is RAS-mutated and has progressed during or after treatment with approved therapies or for which there is no standard effective therapy available: :
Colon Cancer with a RAS mutation
Pancreatic Cancer with a RAS mutation
Other Solid Tumor with RAS Mutation
Ocular melanoma, which includes melanoma that develops in the sclera, retina, uvea (iris, choroid layer, and ciliary layer), or conjunctiva
Glioblastoma with a RAS mutation or EGFR alteration
Phase 1 and phase 2 advanced solid tumor cohorts excluding GBM: Measurable or evaluable disease by RECIST v1.1
Phase 2 GBM only: Pathologically confirmed high-grade glioma (WHO grade 3 or 4) with a RAS mutation or altered EGFR, with documented CT or MRI progression or recurrence. Biopsy is also an acceptable method of confirming progression. If initial tumor was grade 2 glioma, histological confirmation of high-grade recurrence is required
Phase 2 GBM only: Measurable or evaluable disease by RANO (MRI) or Macdonald (CT) criteria
Phase 2 GBM only: Fixed or decreasing dose of corticosteroids (or no corticosteroids) for at least 1 week prior to cycle 1 day 1.
Phase 2 GBM only: At least 12 weeks since the completion of radiation therapy to a total of ≥ 50 Gy

All patients must meet all of the following inclusion criteria to be eligible to participate in the study:

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate bone marrow function
Absolute neutrophil count (ANC) ≥ 1500/mm3
Platelets ≥ 100,000/mm3
Hemoglobin > 9 g/dL (untransfused)
Adequate renal function
Creatinine ≤ 1.5 x upper limit of normal (ULN) for the laboratory or calculated or actual creatinine clearance ≥ 60 mL/min
Adequate hepatic function
Total bilirubin ≤ 1.5 x ULN for the laboratory Exception: If a patient has documented Gilbert's syndrome and a total bilirubin is > 1.5 x ULN for the laboratory, the total bilirubin requirement may be waived provided the direct bilirubin is within normal limits (WNL) for the laboratory.
Aspartate aminotransferase (AST) ≤ 3.0 x ULN for the laboratory
Alanine aminotransferase (ALT) ≤ 3.0 x ULN for the laboratory
Note: For the expansion cohorts, in patients with documented liver metastasis, the AST and ALT requirements will be ≤ 5 x ULN for the laboratory
Non-hematologic toxicities from previous cancer therapies resolved to ≤ grade 1 except chronic residual toxicities that in the opinion of the investigator are not clinically relevant given the known safety/toxicity profiles of neratinib and sodium valproate (eg, alopecia, changes in pigmentation, stable endocrinopathies, neuropathy, skin toxicities)
International normalized ratio (INR) is ≤ 1.5 and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN for the laboratory
Left ventricular ejection fraction (LVEF) within 3 months prior to initiation of study treatment indicates an LVEF of ≥ 50%.
A woman of childbearing potential (WCBP), defined as a woman who is < 60 years of age and has not had a hysterectomy, must have a documented negative serum pregnancy test within 7 days prior to initiating study treatment
WCBP and a male patient with a partner who is a WCBP must agree to use a medically accepted method for preventing pregnancy for the duration of study treatment and for 2 months following completion of study treatment
Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria:

Phase 1 and phase 2 advanced solid tumor cohorts excluding GBM: Current or prior known meningeal metastases
Phase 1 and phase 2 advanced solid tumor cohorts excluding GBM: Known brain metastases that are symptomatic or untreated Note: Patients with known brain metastases who are asymptomatic and have had post-treatment imaging that indicates stable brain disease are eligible. Note that brain imaging in patients with known brain metastases is required within 8 weeks prior to initiation of study therapy.
Any investigational agent within 4 weeks prior to initiating study treatment
Previous therapy with neratinib
Active uncontrolled diarrhea leading to dehydration or electrolyte disturbances not easily controlled with oral repletion
Inability to swallow medication
Known or suspected malabsorption condition or obstruction. Note: Use of pancreatic enzyme supplements is allowed to control malabsorption
Inability to shift medications as follows: Antacids (eg, calcium carbonate): dose at least 3 hours after dosing with neratinib. H2 receptor antagonists: dose must be taken at least 2 hours after or 10 hours before dosing with neratinib
Resting systolic blood pressure (BP) < 100 mmHg
Active or clinically significant cardiac disease including any of the following:
Unstable angina (eg, anginal symptoms at rest) or onset of angina within 3 months prior to initiating study treatment
Myocardial infarction diagnosed within 6 months prior to initiating study treatment
Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers
New York Heart Association (NYHA) class III or IV congestive heart failure
Seizure disorder requiring an enzyme inducing antiepileptic medication (EIAED)
Serious (ie, ≥ grade 3) uncontrolled infection
Chronic or active hepatitis B or C infection with elevated transaminase levels
Pleural effusion or ascites that causes respiratory compromise (ie, ≥ grade 2 dyspnea)
Known mitochondrial disorder caused by mutations in mitochondrial DNA polymerase gamma (γ)
Known urea cycle disorders
Planned ongoing treatment with other drugs thought to potentially have adverse interactions with either of the medications included in the study treatment:
Cosyntropin
Proton pump inhibitors (PPIs)
High-risk P-glycoprotein (P-gp) substrates (eg, digoxin, dabigatran, fexofenadine). Other anticoagulants are not considered high-risk P-gp substrates
Strong or moderate CYP3A4 inhibitors and/or Strong or moderate CYP3A4 inducers. Examples of clinical inhibitors and clinical inducers for P450-mediated metabolism and classification of strong, moderate, and weak interactions are available through the

FDA website, Tables 3-2 and 3-3:

http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteracti onsLabeling/ucm093664.htm Note: If such medications have been used, patients must have discontinued these agents ≥ 2 weeks prior to initiating study treatment

Pregnancy or breastfeeding
Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements